Description
Gefitinib
Each film-coated tablet contains: Gefitinib … 250 mg.
INDICATIONS
LuciGefi is a tyrosine kinase inhibitor indicated for the first -line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Limitation of Use: Safety and efficacy of LuciGefi have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
DOSAGE AND USE
Recommended dose is 250 mg orally, once daily with or without food.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS
Keep medicine out of reach of Children. Do not administer LuciGefi during Pregnancy and Lactation
Reviews
There are no reviews yet.